Join our experts, Drs Liebowitz and Mehta, as they provide insights on the differential diagnosis and management concepts in autoinflammatory diseases. Sponsored by Novartis Pharmaceutical Corporation. https://t.co/b9PNCOiL7q https://t.co/7n5DwdmaIQ

Higher Rates of Childlessness in Rheumatic Diseases A Finnish population study shows that several rheumatic diseases may impair reproduction and pregnancy outcomes, with significantly higher rates of childlessness or fewer children overall for women. https://t.co/pBoSBGGMxA https://t.co/j8RGT9qrKL

ACR Supports FY 2024 Budget The ACR expressed strong support for several key measures included in the Fiscal Year (FY) 2024 budget. https://t.co/rviB0yKxOd https://t.co/LY8AzsgWjX

September 2023, CDC’s recommended the updated 2023–2024 booster COVID Vaccine (monovalent XBB.1.5). MMWR study shows only 18% of high risk (immunocompromised) recv'd it. Vax was 38% effective at preventing COVID hospitalization https://t.co/vf5jkMkPwj https://t.co/c55SuIuaDb

GEM: Dysphagia in myositis pts is from skeletal muscle involvement, causing upper pharyngeal dysphagia, but may also manifest as dysphonia, nasal regurgitation, or aspiration (w/ risk of pneumonia). https://t.co/7UMHcX7suO

>25% of elderly fall each yr; falls are leading cause of injury-related death in > 65 yrs. PT & Functional exercises to improve leg strength and balance are recommended for fall prevention in @risk populations & show 20-30% less risk overall https://t.co/IPQoS4dUpS https://t.co/qUEwLX0KEq

Wrist pain differential diagnoses beautifully demonstrated 👍 Remamber that radial-sided wrist pain is more common that ulnar-sided wrist pain. https://t.co/3Ite2FsYtl

Predicting Vasculitis Relapse Scores on a patient-reported sino-nasal symptom questionnaire were associated with subsequent flares of one type of ANCA-associated vasculitis (AAV), researchers said. https://t.co/2IjrXiGbIA https://t.co/4uTsa6mc77

Chikungunya Arthritis - 2 studies show benefit of dexamethosone (up to 4mg/d) w/ improved DAS28 scores; Uncertain benefit however with MTX; 133 Brazilian pts studied for 5 mos & 31 pts studied for 8wks. https://t.co/Ko3aRYX0xi https://t.co/rtC4RCRjnU https://t.co/XOoFYw0dR4

Long term outcomes of phase III KEEPsAKE 2 trial in #PsA; SC risankizumab 150 mg given q12wks (after wk 24). 78% were ongoing. RZK achieved 60% ACR20 at wk 52, 57% ACR20 at wk 100, & 75% maintained ACR20 to wk 100. MDA achieved in 34% & 33%.https://t.co/juYQklrhG3 https://t.co/8uhmydPZDf

Cabaletta Bio announced FDA has granted Orphan Drug Designation to CABA-201, a 4-1BB-containing human CD19-CAR T cell agent, to treat systemic sclerosis. RESET (REstoring SElf-Tolerance) trial program includes the Phase 1/2 RESET-SSc trial https://t.co/SWAwLs4PzG https://t.co/3yJ8zlhN9C